Skip to contents

Peter Andrija Nigrovic, MD
Associate Physician, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Rheumatology, Immunology
75 Francis Street
Boston, MA 02115

Edit Profile

Research Narrative:
My laboratory studies basic mechanisms of inflammatory arthritis, in particular the pathways by which IgG antibodies trigger joint inflammation. Two groups within my lab work on related aspects of this biology:
1) Innate immune responders within the joint – mast cells, neutrophils and platelets. We found that synovial mast cells “jump start” arthritis by elaborating IL-1 production upon triggering via IgG and complement. The IL-1 family cytokine IL-33 promotes this effect both by priming mast cells to respond to immune complexes and by supporting mast cell survival in inflamed tissues. We found that the neutrophil surface protein Ly6G participates in a new mechanism regulating integrin-dependent migration, and that this mechanism can be targeted to block experimental arthritis. We are currently studying a potential human homolog. We helped identify platelet microparticles as a key inflammatory mediator in arthritis and continue to study the pro-inflammatory role of this lineage.
2) IgG Fc glycosylation as a modulator of antibody function. The function of IgG is modulated by variable sugars (glycans) that shape the protein structure of the IgG Fc and thereby modulate interaction with Fc receptors and complement. We study how these glycans change with age, gender, and disease, principally inflammatory arthritis. We are particularly interested in the role of IgG glycans in juvenile idiopathic arthritis (JIA) and as a regulator of humoral immunocompetence in children.
I am a medicine/pediatrics-trained rheumatologist with appointments at BWH and Boston Children’s Hospital, and direct the Center for Adults with Pediatric Rheumatic Illness (CAPRI) at BWH. I direct arthritis biorepositories at BWH and Children’s. I have an active interest in mentoring junior faculty, and started both a local Aims Review Committee to support grant writing and a nationwide inter-institutional mentoring program within pediatric rheumatology, termed AMIGO (the ACR/CARRA Mentoring Interest Group), that serves more than half of pediatric rheumatology fellows and junior faculty in the US and Canada

Harvard Medical School, 1995, MD

Mast Cell Culture